Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Autologous CIK Cells(Siriraj Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Autologous CIK Cells(Siriraj Hospital): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CD19/CD22 CAR-T (Essen Biotech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
CD19/CD22 CAR-T (Essen Biotech): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
EB-NK-301 (Beijing Biotech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
EB-NK-301 (Beijing Biotech): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
PepGNP-SARSCoV2 (Emergex Vaccines) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
PepGNP-SARSCoV2 (Emergex Vaccines): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Anti-CD30 CAR T-cell therapy(Bio-Raid) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Anti-CD30 CAR T-cell therapy(Bio-Raid): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Secretome(Baermed) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Secretome(Baermed): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
JY-231 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
JY-231: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
TolDCB29 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
TolDCB29: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CARTemis-1 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
CARTemis-1: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
MSP3-CRM-Vac4All/Alhydrogel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
MSP3-CRM-Vac4All/Alhydrogel: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Anti-CEA CAR T cell therapy(Shanghai Genechem Co., Ltd.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Anti-CEA CAR T cell therapy(Shanghai Genechem Co., Ltd.): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
8 min read
MG-S-2525 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
MG-S-2525: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.